Daniel Carpenter, Reputation and Power
Organizational Image and Pharmaceutical Regulation at the FDA
Bibliographic Data
| ID | 12210591 |
|---|---|
| Authors | Lucas Richert (0000-0002-5593-4383, University of Saskatchewan, corresponding author) |
| Year | 2011 |
| Volume | 24 |
| Issue | 2 |
| Pages | 526-527 |
| Publication date | 2011-06-23 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Social History of Medicine (JOURNAL) |
| Journal identifiers | ISSN: 0951-631X • E-ISSN: 1477-4666 |
| Publisher | Oxford University Press (OUP) (PUBLISHER) |
| DOI | 10.1093/shm/hkr083 |
| OpenAlex | W2095687745 |
| Language | EN |
The latest volume from Princeton University Press's fine series in American politics, Reputation and Power charts the regulation of pharmaceuticals over the past century. Daniel Carpenter's book, at 802 pages, is ambitious in scope and rich in detail. While its prose may not be the most colourful, this is the definitive work on the regulation of drugs in the United States and also one of the most trenchant and thorough explorations of a US government agency. Carpenter's 12 lengthy chapters heave with information. Chapters 1 through 6 describe the growth of the modern system of pharmaceutical oversight, while Chapters 7 through 11 showcase the operation of that system. Along the way, Carpenter includes 28 illustrations and 26 tables representing his extensive quantitative analysis. He examines, for instance, the number of newspaper articles mentioning thalidomide as well as the percentage of new molecular entities rejected or withdrawn between 1976 and 1998
Agency (philosophy · Government (linguistics · Law and economics · Newspaper · Operations research · Political science · Politics · Power (physics · Reputation · Scope (computer science · Social science · Sociology · Computer Science · Engineering · Pharmaceutical industry and healthcare · History · Law · Philosophy
| Highly cited | No |
|---|